



**iCare Psychiatry**

A Behavioral Wellness Center

6759 West Charleston Blvd Suite 130 Las Vegas NV 89146

702-227-4165 Fax 702-227-7921 email: [admin@icarepsychiatry.com](mailto:admin@icarepsychiatry.com)

[www.icarepsychiatry.com](http://www.icarepsychiatry.com)

Sept 14 2021

Pharmacy & Therapeutics committee  
State of Nevada Department of Health and Human Services  
Division of Healthcare Financing and Policy  
1100 E William street Suite 101  
Carson City NV 89701

RE: annual review- Established Drug classes being reviewed. Due to the release of New Drug psychotropic agents: Antipsychotics: Atypical Antipsychotics-oral

I have been informed of the upcoming annual review including atypical antipsychotics on the preferred drug list to be reviewed September 23rd 2021. I request that Rexulti (Brexipiprazole) tablets continue to be made available and maintain preferred formulary status for patients with Major Depressive Disorder and Schizophrenia. I have prescribed Rexulti and have had favorable results. Having the ability to prescribe Rexulti first line rather than go through multiple trials and failures of other generic medications that may have side effects profiles that could have negative impact on patients. I have also had positive outcomes using Rexulti as Adjunct therapy treating Major Depressive patients.

Rhigel A. Tan P APRN RN GNP ANP PMHNP FAAN  
Doctor of Nursing Practice  
Advanced Nurse Practitioner NV Lic APRN000724

***Personalized Medicine, Individualized Care, Quintessentially You!***